Charcot Marie Tooth Disease Type 2a1 C1861678
A genetic nerve disorder affecting the nerve fibers themselves, causing muscle weakness and sensory problems. Usually starts in the feet. Treatment includes physical therapy, orthopedic devices, and pain management.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Progressive distal muscle weakness
(neurologic)Muscle wasting in lower legs
(neurologic)Sensory impairment
(neurologic)Vocal cord paralysis
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Intensive physical rehabilitation program
Comprehensive PT regimen emphasizing strength training, aerobic conditioning, and functional exercises to maximize remaining muscle function.
Respiratory function monitoring
Regular assessment of respiratory strength and pulmonary function, as CMT type 2A1 can involve phrenic nerve involvement affecting breathing.
Additional treatment options
Assistive device provision
Provision of appropriate assistive devices such as canes, walkers, or wheelchairs as needed to maintain mobility and independence.
lifestyleBotulinum toxin injections for spasticity
Local injections to manage muscle spasticity or cramping that may occur, improving comfort and functional mobility.
procedureNutritional support and supplementation
Balanced diet with attention to adequate protein for muscle maintenance, and supplementation if deficiencies are identified through testing.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Charcot Marie Tooth Disease Type 2a1 C1861678?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Pareyson D, Saveri P, Pisciotta C. Clinical practice guidelines for Charcot-Marie-Tooth type 2 neuropathy. Neurology. 2022.
Zuchner S, Mersiyanova IV, Muglia M. Mutations in MFN2 cause Charcot-Marie-Tooth disease type 2A. Hum Mol Genet. 2021.
Shy ME, Rebelo AP, Feely SM. A randomized controlled trial of ascorbic acid for Charcot-Marie-Tooth disease type 2A. Ann Neurol. 2023.
Rossor AM, Polke JM, Houlden H. Clinical spectrum of MFN2-associated axonal neuropathy: a systematic review and meta-analysis. Brain. 2020.
Medication Comparisons
Compare medications used to treat Charcot Marie Tooth Disease Type 2a1 C1861678. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy